Sector consensus Neurocrine Biosciences, Inc.

Equities

Market Closed - Nasdaq Other stock markets 01:30:00 08/07/2025 am IST			5-day change	1st Jan Change
127.88 ^USD	-0.95%		+1.74%	-6.32%

07/07	RBC Raises Price Target on Neurocrine Biosciences to $146 From $145, Keeps Outperform Rating	MT
01/07	Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell Midcap Value Index	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Average Target P.	Ecart obj. / dr	Nbr of analysts
NEUROCRINE BIOSCIENCES, INC.		$160.19	+24.08%	25
ELI LILLY AND COMPANY		$951.98	+21.94%	27
JOHNSON & JOHNSON		$169.23	+8.47%	23
ABBVIE INC.		$209.12	+10.48%	27
NOVO NORDISK A/S		DKK 645.23	+42.97%	22
ROCHE HOLDING AG		CHF 302.68	+16.41%	20
NOVARTIS AG	-	CHF 119.55	-3.35%	19
ASTRAZENECA PLC		GBX 183.34	+30.02%	20
MERCK & CO., INC.		$101.79	+25.77%	24
AMGEN INC.		$314.27	+5.37%	28
PFIZER, INC.		$29.06	+14.48%	23
GILEAD SCIENCES, INC.		$116.77	+4.49%	26
SANOFI		€113.34	+36.08%	23
VERTEX PHARMACEUTICALS INCORPORATED		$499.87	+8.76%	28
BRISTOL-MYERS SQUIBB COMPANY		$57.1	+21.69%	22
CHUGAI PHARMACEUTICAL CO., LTD.		JP¥8,353.57	+17.24%	14
GSK PLC		GBX 16.61	+18.22%	19
JIANGSU HENGRUI MEDICINE CO., LTD.		CN¥65.39	+22.78%	18
TAKEDA PHARMACEUTICAL COMPANY LIMITED		JP¥4,946.56	+11.41%	16
Average		913.45	+17.75%	22
Weighted average by Cap.		606.71	+18.04%	23